A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

NCT00196872 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicine
DRUG: Cyclophosphamide
DRUG: Taxol
DRUG: Xeloda
DRUG: Ibandronat

Sponsor

GBG Forschungs GmbH